Novo Nordisk slashes prices in some markets and launches Wegovy subscriptions as new clinical data shows edge over Eli Lilly’s rival drug.

Facing intensifying competition in the weight-loss drug market, Danish pharmaceutical giant Novo Nordisk is implementing a dual-track strategy. The company is deploying defensive pricing in some regions while introducing new subscription models in others, all as fresh clinical data provides a boost against its primary rival, Eli Lilly.

Clinical Data Offers Competitive Edge

Recent research findings have delivered positive news for Novo Nordisk’s pipeline. Data from the ORION study, presented in early April, indicates that a 25-milligram oral version of Wegovy leads to an average weight reduction of 16.6%. This result, in an indirect comparison, surpasses the 12.4% weight loss associated with Eli Lilly’s newly approved rival drug, Foundayo.

Furthermore, the study reported fewer patients discontinuing treatment due to side effects. These outcomes hold significant strategic value, given that Eli Lilly currently commands over 60% of the U.S. market for obesity medications.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Defensive Moves and New Commercial Approaches

In key growth markets, the firm is adopting a defensive posture to protect its market share. The trigger for this shift is the expiration of international patents, which has led to an influx of lower-cost semaglutid generics. In India, for instance, prices for the blockbuster drugs Wegovy and Ozempic have been slashed by up to 48%. This pricing pressure is reflected in the stock’s performance: the share price has declined by 47.7% over a one-year period, currently trading at 31.96 euros.

For more established markets, a different approach is underway. The company has launched a new subscription model for Wegovy, specifically targeting self-paying patients. Through a partnership with the telemedicine platform LifeMD, patients can commit to three, six, or twelve-month plans. This structure aims to minimize unpredictable costs for users and improve treatment adherence.

Management Maintains Cautious Stance

Despite the encouraging trial results, Novo Nordisk’s leadership remains conservative in its outlook for the remainder of 2026. Current forecasts project a currency-adjusted decline in both revenue and operating profit, ranging between 5% and 13%.

This anticipated downturn is attributed primarily to pricing agreements in the United States, reduced Medicaid subsidies for obesity treatments, and margin compression from new oral therapies introduced by competitors. The next major operational milestone is expected by the end of 2026, with a regulatory decision on the approval of the combination drug CagriSema.

Ad

Novo Nordisk Stock: New Analysis – 4 April

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis…